中外企业抢占百亿美元规模银屑病市场,价格战即将打响

第一财经
Dec 15, 2024

全文1140字,阅读约需4分钟,帮我划重点划重点01随着强生等巨头原研药专利到期,国产生物类似药陆续上市并进入医保,银屑病药物市场在中国将迎来激烈竞逐。02目前,强生的原研药乌司奴单抗在银屑病生物制剂市场上占据头部地位,2023年在中国销售额超过13亿元人民币,全球销量突破100亿美元。03随着国产生物类似药的上市,有望改变国内银屑病治疗格局,提高国内用药的可及性,弥补临床治疗中的需求空缺。04...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10